跳至主要内容
临床试验/NCT02068859
NCT02068859Unknown3 期

Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1%

FPR Specialty Pharmacy1 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2014年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
发起方
入组人数
106
试验地点
1
主要终点
Descrete Response Scale Pain Scores

研究概览

简要总结

Non-steroidal anti-inflammatory medication (NSAID) therapy is a mainstay treatment for joint pain and painful musculoskeletal disorders. Though this form of systemic therapy is highly effective, it causes substantial side effects including gastritis and gastric ulcer disease, renal impairment, hypertension, and thrombotic events. These types of oral medications are utilized by millions of Americans on a fairly regular basis in both over-the-counter preparations and prescription compounds. In recent years, topical preparations of NSAIDs have been used for localized pain as an alternate to oral administration with reported good analgesic efficacy. For example, they are often used for knee pain. There is little systemic absorption of NSAIDs with topical administration, and consequently less likelihood of systemic side effects.

Though much less studied than oral NSAIDs, topical NSAID preparations are currently prescribed for a variety of arthritic and musculoskeletal types of pain. The best-studied commercially available products are diclofenac 1% compounds. Higher concentrations presumably provide higher tissue concentration leading to better and longer pain relief, along with a more prominent anti-inflammatory effect.

The investigators will therefore compare the efficacy of available topical diclofenac 1% gel to that of diclofenac 8% cream. Specifically, the investigators propose to test the hypothesis that efficacy of topical diclofenac 8% exceeds that of diclofenac 1%, without any increase in systemic toxicity.

One hundred six patients presenting to the Cleveland Clinic Pain Management Department for the treatment of knee pain will be randomly assigned to topical diclofenac cream 8% or diclofenac gel 1%, with the designated medication applied the symptomatic area of the knee over 6 weeks. Investigators will be blinded to treatment, and will evaluate pain relief and functional/disability status.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Acute and chronic knee pain, along with postoperative knee pain lasting at least two months.

排除标准

  • Patients will be excluded if deemed inappropriate for application of topical medication therapy by the treating physician. This will include adult patients with diffuse (non-localized) pain disorders and those likely to need knee surgery during the treatment period.
  • Patients with knee infection, open knee wounds, or acute knee skin lesions will be excluded.
  • Patients with diclofenac or wheat or gluten allergies will also be excluded.

研究组 & 干预措施

Diclofenac Cream 8%

Experimental

Diclofenac Cream 8% applied 3-4 times daily for 6 weeks.

干预措施: Diclofenac Cream 8% (Drug)

Control

Active Comparator

Diclofenac Gel 1% applied 3-4 times daily fr 6 weeks

干预措施: Diclofenac Gel 1% (Drug)

结局指标

主要结局

Descrete Response Scale Pain Scores

时间窗: Daily measurement for 6 weeks

Patients will maintain a daily home pain diary. This will be recorded in the evening each day over the six week treatment period with documentation of minimum, maximum, and overall average daily pain on a 0-10/10 discrete response scale (DRS).

次要结局

未报告次要终点

研究者

发起方
FPR Specialty Pharmacy
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Treatment of Knee Pain With Topical Diclofenac Cream... | 临床试验